Zavante Therapeutics is a leading biopharmaceutical company dedicated to developing innovative antibiotics that combat infectious diseases. With locations in the United States, Austria, and Ireland, Zavante is committed to addressing the urgent problem of bacterial resistance on a global scale. Their flagship product, lefamulin, is the first pleuromutilin antibiotic that can be administered orally or intravenously for the treatment of community-acquired bacterial pneumonia (CABP).

Lefamulin has successfully completed two pivotal Phase 3 trials, meeting the primary endpoints set by the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The FDA has granted Qualified Infectious Disease Product and Fast Track designation to both formulations of lefamulin. Zavante also offers CONTEPO™, a potentially groundbreaking intravenous antibiotic with broad-spectrum activity against Gram-negative and Gram-positive bacteria. Although currently in the approval process for complications of urinary tract infections, CONTEPO™ has a long-standing commercial history outside the United States.

By pursuing business development opportunities and collaborations, Zavante aims to become a fully integrated biopharmaceutical company committed to revolutionizing the field of anti-infectives